The Respiratory Complications Therapeutics Market to Reach $30.2 Billion in 2022 from $21.8 Billion in 2015

Global Respiratory Complications Therapeutics Market Analysis report summarizes Innovative Pneumonia, Pulmonary Arterial Hypertension Therapies, Dominate Varied Disease and active development in the respiratory complications pipeline.

The Respiratory Complications Therapeutics Market report "Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market" provides an introduction to the respiratory complications therapeutics market, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications, diagnosis and prognosis.

Browse Complete 80 Tables and Figures, Top Leading Company Profiles, spreads across 197 pages available @ .

Respiratory complications are a diverse set of indications that include respiratory disorders, cardiovascular disorders and infectious diseases. They are therefore associated with a broad range of underlying pathophysiology, which is reflected in the range of therapies in development in the pipeline. Overall, there are 843 products in active development in the respiratory complications pipeline. However, this constitutes numerous individual indications, each of which is typically relatively small in terms of the number of pipeline products in development.

The most prominent individual indications in terms of respiratory complications therapeutics development are Pneumonia, Tuberculosis (TB), Respiratory Syncytial Virus (RSV) and Pulmonary Arterial Hypertension (PAH), which reflects the active nature of these indications in terms of overall product development.

In spite of a small late-stage pipeline, the respiratory complications market is forecast to grow moderately over the forecast period, from a value of $21.8 Billion in 2015 to $30.2 Billion in 2022, at a compound annual growth rate (CAGR) of 4.7%. This growth will be predominantly driven by already marketed products, rather than the approval of pipeline products, which are expected to have a limited impact on the market. Furthermore, generic impact on the market will be limited in terms of value, given the very low cost of generics typically used.

Order a Single or Corporate User License Copy @ .

There are few drugs that generate substantial revenue in the current respiratory complications market, with only one generating over $1 Billion from revenues specific to these complications. This is the Prevnar family pneumococcal disease vaccine, which has been approved for a broad spectrum of patients, ranging from six-week-old infants to adults of 50 and over. In 2015 the vaccine family generated $6.3 Billion, and this level of revenue is expected to remain relatively stable over the forecast period.

Pfizer is expected to maintain its position as market leader throughout the entire forecast period. Although the company has a large number of drugs active in this area, spread across pneumonia and pulmonary embolism, it is predominantly the pneumonia vaccine Prevnar that drives its revenue derived from respiratory complications. Pfizer is expected to generate $7.3 Billion by 2022, rising from $6.9 Billion in 2015 at a CAGR of 0.8%. This marginal growth is attributed to the limited revenue growth of Prevnar, as well as some revenue growth for the anticoagulant Eliquis (apixaban), which is expected to generate $642.8m from respiratory complications by 2022.

Reasons to buy:
Understand the current clinical and commercial landscape through a comprehensive study of disease epidemiology, pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report, which include pneumonia, TB, RSV and PAH.

Assess the current treatment landscape, with product profiles covering prominent marketed therapies, including revenue forecasts. Analyze the respiratory complications pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.

Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The Respiratory Complications Therapeutics Market report will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.

Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from respiratory complications products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market. Identify commercial opportunities in the respiratory complications deals landscape by analyzing trends in licensing and co-development deals.

Major Table of Content: Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market Report
Marketed Products
Pipeline Landscape Assessment
Multi-scenario Market Forecast to 2022
Company Analysis and Positioning
Strategic Consolidations
List of Tables
List of Figures

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Phone: 1888 391 54 41

Release ID: 187481